I could not really understand all the science in the article...but I did understand this part...
"With very important data coming in the next 3-4 months, we believe Neurocrine shares, already attractively valued based on elagolix, could have another nice leg-up if NBI-98854 succeeds."
Hi Guys ..
Intelgenx launched their first drug Forfivo in October this will drive Intelgenx into Profitability this Year because of its very low burn-rate of around $1.2 Mil a year !
IGXT Submits NDA for Anti-Migraine Versafilm to FDA in March another 1x NDA filing for Erectile Dysfunction Versafilm and 2x ANDA filings expected in 1H 2013. Two Partnerships for Anti-Migraine and Erectile Dysfunction products is expected in 1H 2013 too which means more Cash for Intelgenx .Intelgenx has 9x Drugs in late stage which will be all on the Market within next 2-3 years .
IGXT has NO DEBT and Cash untill 2016 means enough to drive this Company into Profitability which is expected for this Year . Current Market Cap of just $31 M is really Brutally Underpriced .
IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Market Cap : $31 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year
Price : $0.63
Shares Out : 50 M ( 20 M shares are held by Insiders & Institutions)
March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.
Another new 52H today and more to come
this is a stock with very few retail investors holding shares so its going to be some what volitile which IMO means lower lows and Higher highs as we get VMAT2 data over the summer.
If VMAT shows a positive secondary end point in schizo in August P2 read out.
The stock will go into the low $20's.
No matter what happens this summer I will be hedging my long position with out of the money put options for Elagolix P3 Endo results. No SPA so the p3 results could get called into question by some rogue analyst. We all know how the game is played.
Even with the shares outstanding doubling since the Indiplon crash we could see a $40 share price by mid 2014. if all goes well.
Sentiment: Strong Buy
I see your new high from 3/31 and raise you a new high today. Not sure what's going on (other than NBIX getting noticed for a pipeline full of drugs in trials) but I likey.
Officially starting Elagolix phase IIB trial in UF which is a big deal to NBIX stock; and this up treand will be continued to VMAT2 phase IIB result reported - which will cauase either big jump or collapse based on binary event
Nice POP last Thursday, this stock is heading for $16/$18 on positive VMAT2 p2 studies this summer.
Breaking $12 with brisk volume bodes well for setting up a $10 floor for NBIX on any general market pull back.
Hey short stuff
post your heart out
NBIX is still going higher over the next 6 months
New intra day High $12.44
August is when the second VMAT2 trial should read out top line results. this is the trial that enrolled only schizo patients ........... if we see the drug have an effect via a secondary endpoint VMAT could have the potential of being a pipeline within a pipeline with multi $$billion potential ................ this is my pump for the day .... LOL
Sentiment: Strong Buy
I thought the first trial concentrated on schizo patients.